title: Fifty percent tissue culture infective dose assay for determining the titer of infectious human herpesvirus 8.
abstract: We have developed a human herpesvirus 8 (HHV-8) 50% tissue culture infective dose (TCID50) assay using the T1H6-DC-SIGN cell line. Infection of T1H6-DC-SIGN cells with HHV-8 induces expression of β-galactosidase, which was used to determine TCID50 levels. Validation of TCID50 values was performed by immunofluorescence assay of HHV-8 infection of immature dendritic cells at various TCID50 doses.
authors.affiliation: Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Sagar V
authors.initials: SV
authors.lastname: Nadgir
authors.forename: Heather R
authors.initials: HR
authors.lastname: Hensler
authors.forename: Emilee R
authors.initials: ER
authors.lastname: Knowlton
authors.forename: Charles R
authors.initials: CR
authors.lastname: Rinaldo
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rappocciolo
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Jenkins
mesh_terms: D002460:Cell Line; D003713:Dendritic Cells / Q000821:virology; D017930:Genes, Reporter; D019288:Herpesvirus 8, Human / Q000302:isolation & purification / Q000472:pathogenicity* / Q000502:physiology*; D006801:Humans; D019562:Viral Load / Q000379:methods*; D001616:beta-Galactosidase / Q000032:analysis
chemical_list: D001616:beta-Galactosidase
references.citation: J Virol. 2008 May;82(10):4793-806
references.pmid: 18337571
references.citation: J Virol. 1999 Nov;73(11):9348-61
references.pmid: 10516043
references.citation: J Immunol. 2006 Feb 1;176(3):1741-9
references.pmid: 16424204
references.citation: Mol Cell Biol. 1987 Jan;7(1):379-87
references.pmid: 3031469
references.citation: Blood. 1995 Aug 15;86(4):1276-80
references.pmid: 7632932
references.citation: Br J Cancer. 2003 Nov 17;89(10):2016-7
references.pmid: 14612917
references.citation: J Virol. 2003 Jul;77(14):8147-52
references.pmid: 12829853
references.citation: J Infect Dis. 2007 Sep 15;196(6):844-52
references.pmid: 17703414
references.citation: Infect Agent Cancer. 2010 Nov 18;5:21
references.pmid: 21087485
references.citation: J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1237-50
references.pmid: 2193952
references.citation: AIDS. 1996 Nov;10(13):1596-8
references.pmid: 8931799
references.citation: J Infect Dis. 1997 Jul;176(1):94-102
references.pmid: 9207354
references.citation: J Virol. 1997 Sep;71(9):7083-7
references.pmid: 9261440
references.citation: Antiviral Res. 2011 Jun;90(3):143-50
references.pmid: 21440007
references.citation: Virology. 2007 Mar 15;359(2):425-35
references.pmid: 17074378
references.citation: J Infect Dis. 2004 Jun 1;189(11):2016-22
references.pmid: 15143468
references.citation: Lancet. 1997 Mar 1;349(9052):609-11
references.pmid: 9057733
references.citation: AIDS. 1997 Feb;11(2):249-50
references.pmid: 9030373
references.citation: J Virol. 2000 Dec;74(23):10920-9
references.pmid: 11069986
references.citation: Transplant Proc. 1999 Feb-Mar;31(1-2):922-3
references.pmid: 10083406
references.citation: N Engl J Med. 1998 Nov 5;339(19):1358-63
references.pmid: 9801396
references.citation: J Infect Dis. 2009 May 15;199(10):1449-56
references.pmid: 19351262
references.citation: J Infect Dis. 1998 Jan;177(1):213-6
references.pmid: 9419191
references.citation: Science. 1994 Dec 16;266(5192):1865-9
references.pmid: 7997879